LAMP1 and neoplasm: We found equivalent levels of CD107a + cells in CD19CAR and Akti-treated CD19CAR T cells upon CD19+ tumor stimulation (24.9 ± 15 vs. 27.8 ± 13.4%, respectively) (Fig. 4a and b).